Author

Bonita J. Rup

Observed names: Bonita J Rup, Bonita Rup, Rup, Bonita

Observed institutions: University of North Carolina at Chapel Hill, Monsanto (United States), Beth Israel Deaconess Medical Center, Harvard University, Royal Free London NHS Foundation Trust, Pfizer (United States), Georgetown University, Georgetown University Medical Center, The Royal Free Hospital, University of Rochester Medicine, Wyeth, University of Rochester, The University of Texas at Austin

OpenAlex ID: A5109571306

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

2008 · Eugen Koren, Holly W. Smith, et al. · Journal of Immunological Methods · 328

Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies

2009 · Rafael Ponce, Leslie Abad, et al. · Regulatory Toxicology and Pharmacology · 270

Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics

2007 · Shalini Gupta, Stephen R. Indelicato, et al. · Journal of Immunological Methods · 241

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

2001 · David A. Roth, Craig M. Kessler, et al. · Blood · 188

Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics

2011 · Shalini Gupta, Viswanath Devanarayan, et al. · Journal of Pharmaceutical and Biomedical Analysis · 143

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial

2019 · Raphael Schiffmann, Ozlem Goker‐Alpan, et al. · Journal of Inherited Metabolic Disease · 142

PDF

Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products

2015 · Liusong Yin, Xiaoying Chen, et al. · Cellular Immunology · 88

Avian reticuloendotheliosis virus: Identification of the hematopoietic target cell for transformation

1981 · Robert B. Lewis, Janela McClure, et al. · Cell · 88

Coupling of Aggregation and Immunogenicity in Biotherapeutics: T- and B-Cell Immune Epitopes May Contain Aggregation-Prone Regions

2011 · Sandeep Kumar, Satish K. Singh, et al. · Pharmaceutical Research · 85

Expression of bone morphogenetic proteins in human osteosarcoma. Immunohistochemical detection with monoclonal antibody

1994 · Hideki Yoshikawa, Wolfgang J. Rettig, et al. · Cancer · 81

PDF

Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas

1994 · Hideki Yoshikawa, Wolfgang J. Rettig, et al. · Cancer · 74

PDF

Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple Biotherapeutics

2013 · Li Xue, Bonita Rup · The AAPS Journal · 63

PDF

Critical ligand binding reagent preparation/selection: When specificity depends on reagents

2007 · Bonita Rup, Denise O'Hara · The AAPS Journal · 62

PDF

Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins

2013 · Vera Brinks, Daniel Weinbuch, et al. · Pharmaceutical Research · 60

Helper viruses associated with avian acute leukemia viruses inhibit the cellular immune response

1982 · Bonita J. Rup, Jacalyn D. Hoelzer, et al. · Virology · 55

Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story

2017 · Bonita Rup, Sari Alon, et al. · PLoS ONE · 54

PDF

Immunosuppression Induced by Avian Reticuloendotheliosis Virus: Mechanism of Induction of the Suppressor Cell

1979 · Bonita J Rup, Jean L Spence, et al. · The Journal of Immunology · 46

Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs

2003 · Karen E. Russell, Eva H. N. Olsen, et al. · Blood · 39

Relationship Between Potential Aggregation-Prone Regions and HLA-DR-Binding T-Cell Immune Epitopes: Implications for Rational Design of Novel and Follow-on Therapeutic Antibodies

2012 · Sandeep Kumar, Mark A. Mitchell, et al. · Journal of Pharmaceutical Sciences · 32

Evaluation of Recombinant Human Factor IX: Pharmacokinetic Studies in the Rat and the Dog

1995 · James C Keith, Thomas J Ferranti, et al. · Thrombosis and Haemostasis · 27

Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug Development

2023 · Jochem Gokemeijer, Yi Wen, et al. · The AAPS Journal · 24

Two‐center validation of assays for the detection of binding and neutralizing anti‐factor VIII antibodies

2023 · Jens Müller, Sonja Neimanis, et al. · Haemophilia · 7

PDF

Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell Substrates

2020 · Paul Chamberlain, Bonita Rup · The AAPS Journal · 7

A bridging assay for detection and characterization of anti-drug antibodies to dostarlimab, a new anti-PD-1 therapeutic monoclonal antibody

2021 · Marilyn Patterson, Lee Anne Beausang, et al. · AAPS Open · 4

PDF

VSV replication in normal and transformed T cells, an assay for T suppressor cell activation

1987 · Bonita J. Rup, David W. Scott · Cellular Immunology · 3

Works count: 37

Citation count: 2,217

H-index: 21

I10-index: 21